One Platform, Two Diseases, $97 Million on the Line

Latus Bio closes a $97M Series A to advance gene therapies for CLN2 and Huntington's disease, with human trials expected by Q3 2026

1 Jun 2026

Rare neurological disease has a new backer with deep pockets and a specific theory of victory. Latus Bio closed a $97 million Series A on May 4, 2026, pulling capital from 8VC, DCVC Bio, BioAdvance, and Korea Development Bank, among others, to fund two gene therapy programs in diseases that currently have no approved treatments.

The pitch centers on a proprietary engineered capsid that delivers gene therapies to the brain at lower doses than standard AAV vectors. Less dose means lower safety risk, simpler manufacturing, and a cleaner path to commercial viability. Latus calls this the "large-rare" model: one platform, applied sequentially across underserved diseases with patient populations in the tens of thousands.

Two programs lead the pipeline. LTS-101 targets CLN2, a fatal childhood neurological disorder, carrying FDA Orphan Drug, Rare Pediatric Disease, and Fast Track designations after clearing IND review. A first-in-human trial is expected in Q3 2026, with safety and biomarker data anticipated before year-end. Running in parallel, LTS-201 targets Huntington's disease through MSH3 knockdown, designed to interrupt the somatic instability that drives neurodegeneration, with IND submission planned for the same quarter.

Investor appetite reflects a broader shift. Rare disease gene therapy funding has accelerated sharply in 2026, with the US orphan drug market projected to reach $200 billion by 2031, according to KuicK Research. For institutional backers, a multi-indication platform changes the return math: each successive program carries lower development cost once the capsid is validated.

CNS gene therapy has stumbled before, and the skeptics have receipts. Multiple Huntington's programs have collapsed in human trials after strong preclinical results, and immune responses to viral delivery remain a live clinical concern. Latus Bio's low-dose approach is designed to reduce that risk profile, but the platform has not yet been tested in humans. CLN2 data expected in Q4 2026 will be the first real signal of whether the engineering advantage holds where it matters most. For rare disease investment broadly, that readout could define the mood of the year.